{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:55:34Z","timestamp":1790988934023,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["ICMx"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immune paralysis can be defined as a hypoinflammatory state associated with the incapacity of the immune system to release proinflammatory mediators despite the clearance of pathogens by antimicrobials. Persistent immune paralysis leads to failure to eradicate primary infections with a substantial increase in the risk of multiorgan dysfunction and mortality. The state of immune paralysis is caused mainly by the diminished ability of monocytes to release proinflammatory cytokines in response to endotoxin. This phenomenon is known as endotoxin tolerance. This study aimed to assess the role of dexmedetomidine in modifying immune paralysis in septic shock patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Twenty-four\u00a0patients with septic shock were randomized into two groups of 12 patients. A continuous intravenous infusion of dexmedetomidine started at 0.15\u00a0\u00b5g\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0hr<jats:sup>\u22121<\/jats:sup> and adjusted by 0.15\u00a0\u00b5g\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0h<jats:sup>\u22121<\/jats:sup> to a maximum of 0.75\u00a0\u00b5g\u00a0kg<jats:sup>\u22121<\/jats:sup>\u00a0h<jats:sup>\u22121<\/jats:sup> (10\u00a0ml\u00a0h<jats:sup>\u22121<\/jats:sup>), while midazolam was started at 1\u00a0mg\u00a0h<jats:sup>\u22121<\/jats:sup> (2\u00a0mL\u00a0hr<jats:sup>\u22121<\/jats:sup>) and adjusted by 1\u00a0mg\u00a0h<jats:sup>\u22121<\/jats:sup> to a maximum of 5\u00a0mg\u00a0h<jats:sup>\u22121<\/jats:sup> (10\u00a0mL\u00a0h<jats:sup>\u22121<\/jats:sup>). All infusions were adjusted by increments of 2\u00a0mL\/hr<jats:sup>\u22121<\/jats:sup> to maintain blinding. Serum levels of CD42a+\/CD14+, HLADR+\/CD14+, CRP, IL-6, IL-10 and TNF-\u03b1 were measured at baseline (T1), 12\u00a0h (T2), and 24\u00a0h (T3).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment with dexmedetomidine yielded no significant difference in CD42a+\/CD14+, HLADR+\/CD14, CD24b-MFI, HLADR-MFI, IL6 and TREM1 at all time points when compared with midazolam treatment. There was no significant difference in TLR levels between the two groups. Cardiac output in the dexmedetomidine group showed a significant decrease at 6, 12 and 24\u00a0h (P\u2009=\u20090.033, 0.021, and 0.005, respectively) compared with that in the midazolam group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our results indicated that dexmedetomidine did not affect CD42a+\/CD14+\u2009and HLA-DR+\/CD14+\u2009expression in septic patients. Furthermore, cytokine production and inflammatory biomarkers did not change with dexmedetomidine infusion.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> Clinical trial.gov registry (NCT03989609) on June 14, 2019, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/register.clinicaltrials.gov\">https:\/\/register.clinicaltrials.gov<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40635-023-00542-2","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T07:02:53Z","timestamp":1693810973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Role of dexmedetomidine in modifying immune paralysis in patients with septic shock: randomized controlled trial"],"prefix":"10.1186","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct03989609","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-8123","authenticated-orcid":false,"given":"Mohamed","family":"Elayashy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman A.","family":"Elsayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Mukhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahar","family":"Kasem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara A.","family":"Elmetwally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walaa","family":"Abdelfattah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Ghaith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"10","key":"542_CR1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.it.2009.07.009","volume":"30","author":"SK Biswas","year":"2009","unstructured":"Biswas SK, Lopez-Collazo E (2009) Endotoxin tolerance: new mechanisms, molecules, and clinical significance. Trends Immunol 30(10):475\u2013487. https:\/\/doi.org\/10.1016\/j.it.2009.07.009","journal-title":"Trends Immunol"},{"key":"542_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00018-009-0210-4","volume":"67","author":"MR Yeaman","year":"2010","unstructured":"Yeaman MR (2010) Platelets in defense against bacterial pathogens. Cell Mol Life Sci 67:525\u2013544.  https:\/\/doi.org\/10.1007\/s00018-009-0210-4","journal-title":"Cell Mol Life Sci"},{"key":"542_CR3","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12871-015-0042-8","volume":"15","author":"J Zhang","year":"2015","unstructured":"Zhang J, Wang Z, Wang Y, Zhou G, Li H (2015) The effect of dexmedetomidine on inflammatory response of septic rats. BMC Anesthesiol. 15:68","journal-title":"BMC Anesthesiol."},{"key":"542_CR4","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/ALN.0000000000000491","volume":"3","author":"ML Miranda","year":"2015","unstructured":"Miranda ML, Balarini MM, Bouskela E (2015) Dexmedetomidine attenuates the microcirculatory derangements evoked by experimental sepsis. Anesthesiology 3:619\u2013630","journal-title":"Anesthesiology"},{"key":"542_CR5","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.clineuro.2017.06.012","volume":"160","author":"H Zhou","year":"2017","unstructured":"Zhou H, Lu J, Shen Y, Kang S, Zong Y (2017) Effects of dexmedetomidine on CD42a+\/CD14+, HLADR+\/CD14+ and inflammatory cytokine levels in patients undergoing multilevel spinal fusion. Clin Neurol Neurosurg 160:54\u201358","journal-title":"Clin Neurol Neurosurg"},{"issue":"8","key":"542_CR6","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW et al (2016) The third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 315(8):801\u2013810","journal-title":"JAMA"},{"issue":"8","key":"542_CR7","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1007\/s00134-006-0204-8","volume":"32","author":"G Monneret","year":"2006","unstructured":"Monneret G, Lepape A, Voirin N et al (2006) Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock. Intensive Care Med 32(8):1175\u20131183","journal-title":"Intensive Care Med"},{"issue":"4","key":"542_CR8","first-page":"426","volume":"81","author":"L Hamers","year":"2015","unstructured":"Hamers L, Kox M, Pickkers P (2015) Sepsis-induced immunoparalysis: mechanisms, markers, and treatment options. Minerva Anestesiol 81(4):426\u2013439","journal-title":"Minerva Anestesiol"},{"issue":"12","key":"542_CR9","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1373\/clinchem.2005.052639","volume":"51","author":"WD D\u00f6cke","year":"2005","unstructured":"D\u00f6cke WD, H\u00f6flich C, Davis KA et al (2005) Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 51(12):2341\u20132347","journal-title":"Clin Chem"},{"issue":"1","key":"542_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.5847\/wjem.j.1920-8642.2018.01.009","volume":"9","author":"Y Ma","year":"2018","unstructured":"Ma Y, Yu XY, Wang Y (2018) Dose-related effects of dexmedetomidine on immunomodulation and mortality to septic shock in rats. World J Emerg Med 9(1):56\u201363","journal-title":"World J Emerg Med"},{"issue":"4","key":"542_CR11","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1093\/bja\/aem017","volume":"98","author":"D Memi\u015f","year":"2007","unstructured":"Memi\u015f D, Hekimo\u011flu S, Vatan I, Yand\u0131m T, Y\u00fcksel M, S\u00fct N (2007) Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth 98(4):550\u2013552","journal-title":"Br J Anaesth"},{"issue":"9","key":"542_CR12","first-page":"1274","volume":"35","author":"Y Lu Yang","year":"2015","unstructured":"Lu Yang Y, Zhang X (2015) Effect of Dexmedetomidine on expression of triggering receptor expressed on myeloid cells-1 in lung tissue of rats with sepsis. J Shanghi Jiao Tong Univ Med Sci 35(9):1274","journal-title":"J Shanghi Jiao Tong Univ Med Sci"},{"issue":"6","key":"542_CR13","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bja.2019.07.027","volume":"123","author":"K Wang","year":"2019","unstructured":"Wang K, Wu M, Xu J, Wu C, Zhang B, Wang G, Ma D (2019) Effects of dexmedetomidine on perioperative stress, inflammation, and immune function: systematic review and meta-analysis. Br J Anaesth 123(6):777\u2013794","journal-title":"Br J Anaesth"},{"key":"542_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0165-5728(99)00234-9","volume":"103","author":"J Szelenyi","year":"2000","unstructured":"Szelenyi J, Kiss JP, Vizi ES (2000) Differential involvement of sympathetic nervous system and immune system in the modulation of TNF-alpha production by alpha2- and betaadrenoreceptors in mice. J Neuroimmunol 103:34\u201340","journal-title":"J Neuroimmunol"},{"key":"542_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0165-1781(00)00216-X","volume":"96","author":"M Maes","year":"2000","unstructured":"Maes M, Lin A, Kenis G, Egyed B, Bosmans E (2000) The effects of noradrenaline and alpha-2 adrenoreceptor agents on the production of monocytic products. Psychiatry Res 96:245\u2013253","journal-title":"Psychiatry Res"},{"key":"542_CR16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/ALN.0b013e31819daedd","volume":"110","author":"RD Sanders","year":"2009","unstructured":"Sanders RD, Xu J, Shu Y et al (2009) Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 110:1077\u20131085","journal-title":"Anesthesiology"},{"key":"542_CR17","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri1943","volume":"6","author":"RS Hotchkiss","year":"2006","unstructured":"Hotchkiss RS, Nicholson DW (2006) Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 6:813\u2013822","journal-title":"Nat Rev Immunol"},{"key":"542_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1128\/IAI.71.1.22-29.2003","volume":"71","author":"KE Weatherby","year":"2003","unstructured":"Weatherby KE, Zwilling BS, Lafuse WP (2003) Resistance of macrophages to Mycobacterium avium is induced by alpha2- adrenergic stimulation. Infect Immun 71:22\u201329","journal-title":"Infect Immun"},{"key":"542_CR19","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1645\/GE-3242RN","volume":"91","author":"J Gets","year":"2005","unstructured":"Gets J, Monroy FP (2005) Effects of alpha- and beta-adrenergic agonists on Toxoplasma gondii infection in murine macrophages. J Parasitol 91:193\u2013195","journal-title":"J Parasitol"}],"container-title":["Intensive Care Medicine Experimental"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-023-00542-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40635-023-00542-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40635-023-00542-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:11:35Z","timestamp":1700572295000},"score":1,"resource":{"primary":{"URL":"https:\/\/icm-experimental.springeropen.com\/articles\/10.1186\/s40635-023-00542-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1186\/s40635-023-00542-2","relation":{},"ISSN":["2197-425X"],"issn-type":[{"value":"2197-425X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"assertion":[{"value":"30 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Kasr Alainy Faculty of Medicine, Cairo University Research Ethics Committee (committee Chairperson Professor M. Mohsen Ibrahiem) on 18 May 2019 (N-5-2019). The study was registered on the clinical trial.gov registry (NCT03989609) on June 14, 2019. Informed consent from patients or their legal surrogates was obtained before enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential competing interests with respect to the research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}